Chemours Co CC.N, CC is expected to show a rise in quarterly revenue when it reports results on August 5 for the period ending June 30 2025
The Wilmington Delaware-based company is expected to report a 1.8% increase in revenue to $1.565 billion from $1.54 billion a year ago, according to the mean estimate from 6 analysts, based on LSEG data.The company's guidance on June 18 2025, for the period ended June 30, was for revenue between $1.56 billion and $1.59 billion.
LSEG's mean analyst estimate for Chemours Co is for earnings of 46 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 5 "strong buy" or "buy," 4 "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Chemours Co is $15.00, about 23.3% above its last closing price of $11.50
The company's guidance on May 6 2025 for the period ended June 30 was for Earnings before Interest, Taxes, Depreciation and Amortization of between USD1.55952 billion and USD298.7 million.The company's guidance on May 6 2025 for the period ended June 30 was for Capital Expenditures of USD50 million.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | 0.18 | 0.21 | 0.13 | Missed | -38.9 |
Dec. 31 2025 | 0.12 | 0.12 | 0.11 | Missed | -5.4 |
Sep. 30 2024 | 0.29 | 0.28 | 0.40 | Beat | 40.9 |
Jun. 30 2024 | 0.49 | 0.57 | 0.38 | Missed | -33.6 |
Mar. 31 2024 | 0.19 | 0.18 | 0.32 | Beat | 75 |
Dec. 31 2023 | 0.26 | 0.25 | 0.31 | Beat | 22.2 |
Sep. 30 2023 | 0.70 | 0.69 | 0.63 | Missed | -8.8 |
Jun. 30 2023 | 1.07 | 1.07 | 1.10 | Beat | 2.4 |
This summary was machine generated August 1 at 21:10 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。